VEU240920C52000
- 0.00
- 0.000.00%
Vanguard FTSE All-World ex-US ETF Newsroom
Novartis Lower as BofA Downgrades on Risks to Valuation
Novartis Licenses Gene Therapy Component From Voyager
Novartis Expands U.S. Radiopharma Production Amid Rising Competition
PDD Investors Load Up on Put Options That Could Hedge Against Bigger Stock Slump
Temu Parent PDD Shares Dived 30% on 2Q Revenue Miss, Outlook Commentary
Siemens Healthineers Seeks €200M Novartis Deal to Boost Cancer Imaging Business: FT
Novartis Beats Top-line and Bottom-line Estimates; Raises FY24 Core Operating Income Outlook
Vanguard FTSE All-World Ex-US ETF To Go Ex-Dividend On June 21st, 2024 With 0.4589 USD Dividend Per Share
Novartis, Roche Facing Italy Antitrust Probe Over Lucentis Biosimilar
Travere Gains on Novartis Data for Filspari Rival, Calliditas Buyout
Radiopharma Stocks Higher as Sector Welcomes the Latest M&A Deal
Earnings Call Summary | Novartis AG(NVS.US) Q1 2024 Earnings Conference
Novartis Beats Top-line and Bottom-line Estimates; Raises FY24 Outlook
FDA Requires Labeling Changes to CAR-T Cell Therapies to Reflect Cancer Risk
TG Therapeutics Wins VA Contract for Briumvi
CVS Favors Humira Copycats Hurting AbbVie's Market Share: Evercore
Vertex Pharma Upgraded at Evercore on Alpine Immune Deal
Intra-Cellular Files Lawsuits Challenging Caplyta Generics
AstraZeneca-Fusion Deal Reignites Radiopharma Space
Novartis to Pay up to $835M for STING Antagonist Developer IFM Due